{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:42:57Z","timestamp":1784209377174,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>From 17 to 19th October 2024, the XXI Italian Network for Bio-Immunotherapy of Tumors Meeting (NIBIT) took place in Palermo, in the marvelous historical location of Teatro Politeama, under the auspices of the Italian Association of Medical Oncology (AIOM), Italian Association of Cancer Research (AIRC), Fondazione Pezcoller, Italian Alliance against Cancer (ACC), Italian Lymphoma Foundation (FIL), Grazia Focacci Foundation and Melagioco Foundation. The conference covered a spectrum of topics ranging from target discovery to therapeutic advances in immuno-oncology, bringing world-renowned experts to present groundbreaking innovations in basic, translational, and clinical cancer research. Six sessions focused on cellular therapies, digital pathology, vaccines, tertiary lymphoid structures, and microenvironment in order to get deep insights on how to personalize diagnosis and therapies in the clinical setting. Young investigators had the opportunity to meet and greet their mentors, promoting the synergy of the academic and industrial sectors within the national and international panorama, discussing the application of artificial intelligence on multi-specific antibodies, drug conjugates, and antibody fusion proteins that are advancing the efficacy of precision medicine and minimizing off-target effects.<\/jats:p>","DOI":"10.1186\/s13046-025-03316-8","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T05:02:11Z","timestamp":1739854931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Highlighting recent achievements to advance more effective cancer immunotherapy"],"prefix":"10.1186","volume":"44","author":[{"given":"Beatrice","family":"Belmonte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Benelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bronte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Casorati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mondino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Nistic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Sommaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Tazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Tripodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Francesco","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"18","key":"3316_CR1","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1182\/blood.2022015789","volume":"139","author":"J Westin","year":"2022","unstructured":"Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737\u201346.","journal-title":"Blood"},{"issue":"5","key":"3316_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","volume":"53","author":"SP Robinson","year":"2018","unstructured":"Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2018;53(5):617\u201324.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"3316_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","volume":"19","author":"M Hamadani","year":"2013","unstructured":"Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013;19(5):746\u201353.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"3316_CR4","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, et al. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594\u2013606.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3316_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-021-01113-2","volume":"14","author":"W Hanel","year":"2021","unstructured":"Hanel W, Epperla N. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. J Hematol Oncol. 2021;14(1):104.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"3316_CR6","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, et al. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clin Cancer Res. 2016;22(15):3734\u201345.","journal-title":"Clin Cancer Res"},{"key":"3316_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113392","volume":"195","author":"A Schina","year":"2023","unstructured":"Schina A, Pedersen S, Spenning AL, Laursen OK, Pedersen C, Haslund CA, et al. Sustained improved survival of patients with metastatic melanoma after the introduction of anti-PD-1-based therapies. Eur J Cancer. 2023;195: 113392.","journal-title":"Eur J Cancer"},{"issue":"17","key":"3316_CR8","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1158\/1078-0432.CCR-22-2428","volume":"29","author":"TJ Monberg","year":"2023","unstructured":"Monberg TJ, Borch TH, Svane IM, Donia M. TIL Therapy: Facts and Hopes. Clin Cancer Res. 2023;29(17):3275\u201383.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"3316_CR9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMc2300132","volume":"388","author":"MW Rohaan","year":"2023","unstructured":"Rohaan MW, Kessels R, Haanen JBAG. Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma. Reply N Engl J Med. 2023;388(9):859\u201360.","journal-title":"Reply N Engl J Med"},{"issue":"10","key":"3316_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.annonc.2024.07.723","volume":"35","author":"S Mart\u00edn-Lluesma","year":"2024","unstructured":"Mart\u00edn-Lluesma S, Svane IM, Dafni U, Vervita K, Karlis D, Dimopoulou G, et al. Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis. Ann Oncol. 2024;35(10):860\u201372.","journal-title":"Ann Oncol"},{"issue":"85","key":"3316_CR11","doi-asserted-by":"publisher","first-page":"eadd4817","DOI":"10.1126\/sciimmunol.add4817","volume":"8","author":"O Zimmermannova","year":"2023","unstructured":"Zimmermannova O, Ferreira AG, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, et al. Restoring tumor immunogenicity with dendritic cell reprogramming. Sci Immunol. 2023;8(85):eadd4817.","journal-title":"Sci Immunol."},{"key":"3316_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","volume":"24","author":"CA Chamberlain","year":"2022","unstructured":"Chamberlain CA, Bennett EP, Kverneland AH, Svane IM, Donia M, Met \u00d6. Highly efficient PD-1- targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Mol Ther Oncolytics. 2022;24:417\u201328.","journal-title":"Mol Ther Oncolytics"},{"issue":"7\u20138","key":"3316_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1515\/hsz-2023-0341","volume":"405","author":"A Carr","year":"2024","unstructured":"Carr A, Mateyka LM, Scheu SJC, Bici A, Paijmans J, Reijmers RM, et al. Advances in preclinical TCR characterization: leveraging cell avidity to identify functional TCRs. Biol Chem. 2024;405(7\u20138):517\u201329.","journal-title":"Biol Chem"},{"key":"3316_CR14","doi-asserted-by":"publisher","first-page":"1268698","DOI":"10.3389\/fimmu.2023.1268698","volume":"14","author":"M Svec","year":"2023","unstructured":"Svec M, D\u00f6tsch S, Warmuth L, Trebo M, Fr\u00e4\u00dfle S, Riddell SR, et al. A chimeric antigen receptor-based cellular safeguard mechanism for selective. Front Immunol. 2023;14:1268698.","journal-title":"Front Immunol"},{"issue":"6","key":"3316_CR15","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.immuni.2024.04.021","volume":"57","author":"F De Sanctis","year":"2024","unstructured":"De Sanctis F, Dusi S, Caligola S, Anselmi C, Petrova V, Rossi B, et al. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. Immunity. 2024;57(6):1378-93.e14.","journal-title":"Immunity"},{"key":"3316_CR16","doi-asserted-by":"publisher","first-page":"1229540","DOI":"10.3389\/fimmu.2023.1229540","volume":"14","author":"E Cappuzzello","year":"2023","unstructured":"Cappuzzello E, Vigolo E, D\u2019Accardio G, Astori G, Rosato A, Sommaggio R. How can Cytokine-induced killer cells overcome CAR-T cell limits. Front Immunol. 2023;14:1229540.","journal-title":"Front Immunol"},{"issue":"8","key":"3316_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1199311","volume":"5","author":"E Cappuzzello","year":"2016","unstructured":"Cappuzzello E, Tosi A, Zanovello P, Sommaggio R, Rosato A. Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. Oncoimmunology. 2016;5(8): e1199311.","journal-title":"Oncoimmunology"},{"issue":"9","key":"3316_CR18","first-page":"3037","volume":"109","author":"F Elice","year":"2024","unstructured":"Elice F, Sommaggio R, Cappuzzello E, Riva M, Tisi MC, Bernardi M, et al. A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokineinduced killer cells: a first- in-human case report. Haematologica. 2024;109(9):3037\u201341.","journal-title":"Haematologica"},{"issue":"11","key":"3316_CR19","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","volume":"5","author":"X Zhou","year":"2024","unstructured":"Zhou X, Wang Y, Dou Z, Delfanti G, Tsahouridis O, Pellegry CM, et al. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat Cancer. 2024;5(11):1607\u201321.","journal-title":"Nat Cancer"},{"issue":"1","key":"3316_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41698-023-00466-w","volume":"7","author":"M Garioni","year":"2023","unstructured":"Garioni M, Tschan VJ, Blukacz L, Nuciforo S, Parmentier R, Roma L, et al. Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer. NPJ Precis Oncol. 2023;7(1):112.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"3316_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s42003-022-03296-x","volume":"5","author":"G Bianco","year":"2022","unstructured":"Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, et al. GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers. Commun Biol. 2022;5(1):373.","journal-title":"Commun Biol"},{"issue":"8","key":"3316_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41419-024-06987-x","volume":"15","author":"V Canu","year":"2024","unstructured":"Canu V, Vaccarella S, Sacconi A, Pulito C, Goeman F, Pallocca M, et al. Targeting of mutant-p53 and MYC as a novel strategy to inhibit oncogenic SPAG5 activity in triple negative breast cancer. Cell Death Dis. 2024;15(8):603.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3316_CR23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13046-024-03150-4","volume":"43","author":"V Piastra","year":"2024","unstructured":"Piastra V, Ganci F, Sacconi A, Pranteda A, Allegretti M, Bernardini R, et al. Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer. J Exp Clin Cancer Res. 2024;43(1):234.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3316_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41420-024-02216-8","volume":"10","author":"F Lo Sardo","year":"2024","unstructured":"Lo Sardo F, Turco C, Messina B, Sacconi A, Auciello FR, Pulito C, et al. The oncogenic axis YAP\/MYC\/EZH2 impairs PTEN tumor suppression activity enhancing lung tumorigenicity. Cell Death Discov. 2024;10(1):452.","journal-title":"Cell Death Discov"},{"issue":"6","key":"3316_CR25","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","volume":"174","author":"KK Dijkstra","year":"2018","unstructured":"Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, et al. Generation of Tumor- Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell. 2018;174(6):1586-98.e12.","journal-title":"Cell"},{"issue":"1","key":"3316_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","volume":"15","author":"CM Cattaneo","year":"2020","unstructured":"Cattaneo CM, Dijkstra KK, Fanchi LF, Kelderman S, Kaing S, van Rooij N, et al. Tumor organoid-T-cell coculture systems. Nat Protoc. 2020;15(1):15\u201339.","journal-title":"Nat Protoc"},{"issue":"12","key":"3316_CR27","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s41568-023-00624-z","volume":"23","author":"CM Cattaneo","year":"2023","unstructured":"Cattaneo CM. Identification of personalized cancer neoantigens with HANSolo. Nat Rev Cancer. 2023;23(12):800.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3316_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.ccell.2023.05.009","volume":"41","author":"C Vennin","year":"2023","unstructured":"Vennin C, Cattaneo CM, Bosch L, Vegna S, Ma X, Damstra HGJ, et al. Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity. Cancer Cell. 2023;41(6):1170-85.e12.","journal-title":"Cancer Cell"},{"issue":"9","key":"3316_CR29","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.3390\/ijms22094391","volume":"22","author":"S Mola","year":"2021","unstructured":"Mola S, Pinton G, Erreni M, Corazzari M, De Andrea M, Grolla AA, Martini V, Moro L, Porta C. Inhibition of the Histone Methyltransferase EZH2 EnhancesProtumor Monocyte Recruitment in Human Mesothelioma Spheroids. Int J Mol Sci. 2021;22(9):4391.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3316_CR30","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.devcel.2023.03.001","volume":"58","author":"E D'Imprima","year":"2023","unstructured":"D\u2019Imprima E, Garcia Montero M, Gawrzak S, Ronchi P, Zagoriy I, Schwab Y, et al. Light and electron microscopy continuum-resolution imaging of 3D cell cultures. Dev Cell. 2023;58(7):616-32.e6.","journal-title":"Dev Cell"},{"issue":"9","key":"3316_CR31","doi-asserted-by":"publisher","first-page":"e202104069","DOI":"10.1083\/jcb.202104069","volume":"220","author":"P Ronchi","year":"2021","unstructured":"Ronchi P, Mizzon G, Machado P, D\u2019Imprima E, Best BT, Cassella L, Schnorrenberg S, Montero MG, Jechlinger M, Ephrussi A, Leptin M, Mahamid J, Schwab Y. High-precision targeting workflow for volume electron microscopy. J Cell Biol. 2021;220(9):e202104069.","journal-title":"J Cell Biol"},{"issue":"10","key":"3316_CR32","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/j.cell.2024.03.035","volume":"187","author":"AH Song","year":"2024","unstructured":"Song AH, Williams M, Williamson DFK, Chow SSL, Jaume G, Gao G, et al. Analysis of 3D pathology samples using weakly supervised AI. Cell. 2024;187(10):2502-20.e17.","journal-title":"Cell"},{"issue":"8033","key":"3316_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41586-024-07618-3","volume":"634","author":"MY Lu","year":"2024","unstructured":"Lu MY, Chen B, Williamson DFK, Chen RJ, Zhao M, Chow AK, et al. A multimodal generative AI copilot for human pathology. Nature. 2024;634(8033):466\u201373.","journal-title":"Nature"},{"issue":"11","key":"3316_CR34","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","volume":"20","author":"D Bruni","year":"2020","unstructured":"Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3316_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13046-021-01947-1","volume":"40","author":"A Tosi","year":"2021","unstructured":"Tosi A, Cappellesso R, Dei Tos AP, Rossi V, Aliberti C, Pigozzo J, et al. The immune cell landscape of metastatic uveal melanoma correlates with overall survival. J Exp Clin Cancer Res. 2021;40(1):154.","journal-title":"J Exp Clin Cancer Res"},{"key":"3316_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.579894","volume":"11","author":"MG Narducci","year":"2020","unstructured":"Narducci MG, Tosi A, Frezzolini A, Scala E, Passarelli F, Bonmassar L, et al. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. Front Immunol. 2020;11: 579894.","journal-title":"Front Immunol"},{"issue":"1","key":"3316_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13046-022-02481-4","volume":"41","author":"A Tosi","year":"2022","unstructured":"Tosi A, Parisatto B, Menegaldo A, Spinato G, Guido M, Del Mistro A, et al. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-na\u00efve tumors with immune checkpoint inhibitors. J Exp Clin Cancer Res. 2022;41(1):279.","journal-title":"J Exp Clin Cancer Res"},{"issue":"19","key":"3316_CR38","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.3390\/cancers14194885","volume":"14","author":"D Massa","year":"2022","unstructured":"Massa D, Tosi A, Rosato A, Guarneri V, Dieci MV. Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer. Cancers (Basel). 2022;14(19):4885.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"3316_CR39","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/neuonc\/noac136","volume":"24","author":"G Griguolo","year":"2022","unstructured":"Griguolo G, Tosi A, Dieci MV, Fineberg S, Rossi V, Ventura A, et al. A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. Neuro Oncol. 2022;24(12):2146\u201358.","journal-title":"Neuro Oncol"},{"key":"3316_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105003","volume":"101","author":"F Di Modugno","year":"2024","unstructured":"Di Modugno F, Di Carlo A, Spada S, Palermo B, D\u2019Ambrosio L, D\u2019Andrea D, et al. Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer. EBioMedicine. 2024;101: 105003.","journal-title":"EBioMedicine"},{"issue":"12","key":"3316_CR41","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","volume":"41","author":"E Bergaggio","year":"2023","unstructured":"Bergaggio E, Tai WT, Aroldi A, Mecca C, Landoni E, N\u00fcesch M, et al. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell. 2023;41(12):2100-16.e10.","journal-title":"Cancer Cell."},{"issue":"7","key":"3316_CR42","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/s43018-023-00591-2","volume":"4","author":"I Mota","year":"2023","unstructured":"Mota I, Patrucco E, Mastini C, Mahadevan NR, Thai TC, Bergaggio E, et al. ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nat Cancer. 2023;4(7):1016\u201335.","journal-title":"Nat Cancer"},{"issue":"5","key":"3316_CR43","doi-asserted-by":"publisher","first-page":"e004007","DOI":"10.1136\/jitc-2021-004007","volume":"10","author":"F Riccardo","year":"2022","unstructured":"Riccardo F, Tarone L, Camerino M, Giacobino D, Iussich S, Barutello G, Arigoni M, Conti L, Bolli E, Quaglino E, Merighi IF, Morello E, Dentini A, Ferrone S, Buracco P, Cavallo F. Antigen mimicry as an effective strategy to induceCSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. J Immunother Cancer. 2022;10(5):e004007.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"3316_CR44","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3390\/cancers13040894","volume":"13","author":"R Ruiu","year":"2021","unstructured":"Ruiu R, Barutello G, Arigoni M, Riccardo F, Conti L, Peppino G, Annaratone L, Marchi\u00f2 C, Mengozzi G, Calogero RA, Cavallo F, Quaglino E. Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Targetin Triple Negative Breast Cancer. Cancers (Basel). 2021;13(4):894.","journal-title":"Cancers (Basel)"},{"key":"3316_CR45","doi-asserted-by":"publisher","first-page":"1133177","DOI":"10.3389\/fimmu.2023.1133177","volume":"14","author":"F Celesti","year":"2023","unstructured":"Celesti F, Gatta A, Shallak M, Chiaravalli AM, Cerati M, Sessa F, et al. Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA. Front Immunol. 2023;14:1133177.","journal-title":"Front Immunol"},{"issue":"18","key":"3316_CR46","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med. 2024;391(18):1696\u2013708.","journal-title":"N Engl J Med"},{"key":"3316_CR47","doi-asserted-by":"publisher","first-page":"115141","DOI":"10.1016\/j.ejca.2024.115141","volume":"214","author":"ILM Reijers","year":"2025","unstructured":"Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, et al. Impact of personalized response-directed surgery and adjuvant therapyon survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year datafrom PRADO and OpACIN-neo. Eur J Cancer. 2025;214:115141.","journal-title":"Eur J Cancer."},{"issue":"12","key":"3316_CR48","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1038\/s41591-023-02631-x","volume":"29","author":"I Fraterman","year":"2023","unstructured":"Fraterman I, Reijers ILM, Dimitriadis P, Broeks A, Gonzalez M, Menzies AMM, et al. Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma. Nat Med. 2023;29(12):3090\u20139.","journal-title":"Nat Med"},{"issue":"6","key":"3316_CR49","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178\u201388.","journal-title":"Nat Med"},{"key":"3316_CR50","doi-asserted-by":"crossref","unstructured":"De Martin E, Fulgenzi CAM, Celsa C, Laurent-Bellue A, Torkpour A, Lombardi P, D'Alessio A, Pinato DJ. Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events. Gut. 2024:gutjnl-2024-332125.","DOI":"10.1136\/gutjnl-2024-332125"},{"issue":"2","key":"3316_CR51","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000531744","volume":"13","author":"C Celsa","year":"2024","unstructured":"Celsa C, Cabibbo G, Pinato DJ, Di Maria G, Enea M, Vaccaro M, et al. Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis. Liver Cancer. 2024;13(2):169\u201380.","journal-title":"Liver Cancer"},{"issue":"6","key":"3316_CR52","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jhep.2024.01.018","volume":"80","author":"G Cabibbo","year":"2024","unstructured":"Cabibbo G, Celsa C, Rimassa L, Torres F, Rimola J, Kloeckner R, et al. Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice. J Hepatol. 2024;80(6):957\u201366.","journal-title":"J Hepatol"},{"key":"3316_CR53","doi-asserted-by":"crossref","unstructured":"Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Th\u00fcrlimann B; St Gallen Consensus Conference Panelists 2023. Corrigendum to \"Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early BreastCancer 2023\": [Annals of Oncology 34 (2023) 970-986]. Ann Oncol. 2024:S0923-7534(24)04882-8.","DOI":"10.1016\/j.annonc.2024.11.001"},{"key":"3316_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115097","volume":"213","author":"C Valenza","year":"2024","unstructured":"Valenza C, Trapani D, Zagami P, Antonarelli G, Boscolo Bielo L, Nicol\u00f2 E, et al. Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study. Eur J Cancer. 2024;213: 115097.","journal-title":"Eur J Cancer"},{"issue":"5","key":"3316_CR55","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11864-023-01068-1","volume":"24","author":"C Corti","year":"2023","unstructured":"Corti C, Giugliano F, Nicol\u00f2 E, Tarantino P, Criscitiello C, Curigliano G. HER2-Low Breast Cancer: a New Subtype? Curr Treat Options Oncol. 2023;24(5):468\u201378.","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"3316_CR56","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/CCO.0000000000001087","volume":"36","author":"L Guidi","year":"2024","unstructured":"Guidi L, Boldrini L, Trapani D, Curigliano G. Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances. Curr Opin Oncol. 2024;36(6):487\u201394.","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"3316_CR57","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/jleuko\/qiae023","volume":"115","author":"M Di Simone","year":"2024","unstructured":"Di Simone M, Corsale AM, Toia F, Shekarkar Azgomi M, Di Stefano AB, Lo Presti E, et al. Tumor- infiltrating \u03b3\u03b4 T cells as targets of immune checkpoint blockade in melanoma. J Leukoc Biol. 2024;115(4):760\u201370.","journal-title":"J Leukoc Biol"},{"key":"3316_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.845422","volume":"13","author":"A Brevi","year":"2022","unstructured":"Brevi A, Cogrossi LL, Lorenzoni M, Mattorre B, Bellone M. The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma. Front Immunol. 2022;13: 845422.","journal-title":"Front Immunol"},{"issue":"1","key":"3316_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41392-024-01915-z","volume":"9","author":"RC Schelker","year":"2024","unstructured":"Schelker RC, Fioravanti J, Mastrogiovanni F, Baldwin JG, Rana N, Li P, et al. LIM-domain-only 4 (LMO4) enhances CD8. Signal Transduct Target Ther. 2024;9(1):199.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03316-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03316-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03316-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T05:02:15Z","timestamp":1739854935000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03316-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3316"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03316-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u00a0Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors agree to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}